News & Events

What’s Next Helping Patients Navigate Through Clinical Trial Withdrawal

What’s Next? Helping Patients Navigate Through Clinical Trial Withdrawal

Transitions in care can be difficult for high-risk patients, especially those with cancer who withdraw or are withdrawn from a clinical trial. Transitional care services are therefore essential for high-quality outcomes among these patients, many of whom may be feeling well but are frightened of disease recurrence and uncertain about the future. Transitional care must be implemented to ensure continuity of care and help patients achieve their priorities; however, it is not always given enough attention by researchers. To increase understanding of patients’ experiences during and after trial exit, Dr CM Ulrich, et al, conducted a qualitative survey among patient participants who have withdrawn from clinical trials.

Participants were from a northeast, urban, National Cancer Institute-designated comprehensive cancer center. Of those who consented to the parent study (N = 498), 20 were willing to be interviewed. Most of the patients interviewed were withdrawn from clinical trials because of disease progression; other reasons were adverse effects, acute illness, and 1 unknown. Despite their circumstances, 75% of the participants strongly felt that they wanted to enroll in another trial, viewing clinical trials as the source of breakthrough treatments. Care goals were shaped by consistent values such as having more time to pursue life goals, the benefits of any treatment vs no treatment, and continuing to care for their family or children. Patients reported intense emotions throughout their journey, often relying on support from a social network to help them with coping and with decision-making. Symptoms such as fatigue, pain, dyspnea, neuropathy, and others were reported to have a negative impact on patients’ daily lives, and adverse effects were cited by about one-fourth of patients as their reason for withdrawing from the trial.

Following the interviews, the authors concluded that trial exit should be managed as carefully as trial entry, especially in cancer clinical trials, where patients may face life-limiting illness. Many of the patients expressed respect for their oncologist and staff, and blamed rigid protocols and rules for the withdrawal decision. Some felt these disregarded the physician’s clinical judgment and took away from the individualized care they deserved. When patients withdraw or are withdrawn, physicians should work closely with them to provide a clear path forward to help scared and disappointed participants navigate the next steps along their journey. Patient needs vary, with some requiring advanced care planning or end-of-life discussions, while others will want to discuss alternative interventions or entry into another trial. Overall, improved communication is imperative to help patients transition out of a trial.

High level
Given the risks of trial participation among patients, researchers and healthcare providers have a responsibility to address patients’ post-trial needs and manage transitions responsibly. Coordinated transitional care management should be planned for and implemented to support a patients’ ongoing health journey. When establishing protocols, clinical and research team members should consider how they will manage trial withdrawals, including the types and timing of discussions between researchers and trial participants and their caregivers. Cancer institutions should deliver palliative care concurrently with disease-directed therapies since palliative care consultation has been shown to improve quality of life and emotional states in patients with advanced cancer. In fact, it has been suggested that palliative care specialists be considered part of the care team at trial enrollment, especially for early-phase trials.

Ground level
It is important to acknowledge the risks and contributions of patients participating in clinical trials. More than one-third of the patients in the study expressed a desire to be treated as more than just their disease. Healthcare providers who make their patients feel valued as a person can build a better therapeutic relationship and support the decision-making process. One way to achieve this is to facilitate effective care transitions by providing clear direction as to the care plan and next steps, taking care to incorporate the patient’s goals and preferences. Community oncologists who have an established relationship with their patients may be in an ideal position to put those patients and their caregivers more at ease.

Therapeutic Area

Archives

Matthew Gordon

VP, Real-World Evidence
Matthew has more than 25 years of experience in real-world evidence and observational, non-interventional research. He has led studies across the full life cycle—from startup through publication—supporting objectives that range from understanding a disease’s natural history to fulfilling global safety surveillance requirements. Matthew brings deep expertise in orphan disease programs, having overseen more than 25 long-term, global initiatives, as well as in disease and product registries, prospective pharmacoeconomic studies, and systematic literature reviews. Matthew leads the RWE Registries team, responsible for building the business and team. Prior to joining Aptitude Health, he held senior leadership roles at Parexel, Worldwide Clinical Trials, inVentiv Health Clinical, Quintiles Outcome, and ICON Clinical Research. Matthew holds a BA in sociology from Boston University, is a long-standing member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and is a frequent speaker at ISPOR, the Center for Business Intelligence, and related industry conferences.

Gerald Stanvitch, PhD

VP, Scientific Content

Cate Browning, PhD

VP, Global Medical Affairs

Erin Zingales Rau

VP, Account Services

Kelly Kocor

VP, People & Culture
Kelly leads both the human resources and talent acquisition teams, ensuring that Aptitude Health attracts, retains, and develops top personnel to drive our continued success. With over 17 years of experience transforming global HR initiatives, Kelly is an expert in harmonizing HR policies and fostering a culture of engagement and partnership. She is committed to partnering with all areas of the business to ensure full regulatory compliance and delivering value-added services to our organization and its people. Kelly is passionate about developing and implementing HR strategies that help support our employees’ professional and personal growth. She is dedicated to fostering a culture that encourages innovation, collaboration, and inclusivity, helping Aptitude Health continue to be a great place to work.

Bart Zygmond

VP, Finance
Bart brings a wealth of experience to the organization, having worked in the life sciences, pharmaceuticals, manufacturing, and service industries. With his expertise in financial reporting, US GAAP, SOX, cash flow modeling, and financial analysis, he plays a crucial role in the company’s financial management and strategy. Prior to joining Aptitude Health as VP, Finance, Bart held several controller positions: at Q2 Solutions, he oversaw the global finance team and financial operations, ensuring the accurate and timely financial reporting of the company. He also held controller positions at Domtar Inc and Veristat.

Eugene Vissers, MD

Senior VP, Global Scientific Content
Eugene is a seasoned medical doctor with over 20 years of international experience in pharma, consultancy, and agency environments. Eugene leads the US team of dedicated experts responsible for developing high-quality medical content. Prior to joining Aptitude Health, Eugene served as medical director at Ipsen and AstraZeneca. With both his medical degree and an MBA, Eugene brings a unique perspective to his role. His clinical background, combined with his business acumen, allows him to develop innovative strategies that drive results. Under Eugene’s leadership, the medical content team delivers scientific information of the highest quality, providing valuable insights to our clients around the world.

Adrian Barfield

VP, US Business Development

Kelley Hernandez

Executive VP, US Business Development
Kelley has over 18 years of experience in the oncology space. Kelley joined Aptitude Health after working with Cardinal Health, where she was part of the Healthcare and Analytics Division, and finished her tenure there with VitalSource™ (GPO division). As the leader of the strategic business development team for the US, Kelley brings a wealth of expertise to the organization. Her experience in the healthcare industry, combined with her ability to identify and capitalize on new business opportunities, is invaluable in driving the company’s growth and success. Kelley’s dedication to building strong relationships with life science partners is a testament to her commitment to delivering exceptional value to the healthcare industry.

Adam Sinensky, MBA

Chief Technology Officer

Adam has over 20 years of experience in the healthcare industry and an MBA in healthcare management. After 10 years as a strategy consultant to life science companies, Adam has spent the last decade as a product and strategy leader focused on bringing technology products to market across the payor, provider, and life sciences segments. By combining his business acumen and experience working directly with software developers, engineers, and data scientists, Adam has successfully led numerous product launches and enhancements from ideation to development and go-to-market initiatives. His product and change management expertise has led organizational shifts from services to technology at companies such as Change Healthcare and Datavant/Ciox. At Aptitude Health, Adam is responsible for growing our portfolio of product offerings by leveraging real-world data and artificial intelligence with our existing solutions and industry-leading Axess Network of healthcare providers. He also oversees our IT and cybersecurity teams.

Stefanie Daniels

Chief Commercial Officer

Stefanie is a seasoned healthcare executive with over 20 years of experience in oncology. She brings a wealth of knowledge and expertise to the organization. Stefanie joined Aptitude Health after spending over a decade as a senior director at Physicians’ Education Resource, an oncology CME vendor. During her tenure, she led and managed teams responsible for grant development/acquisition, program creation/execution, and faculty management. Stefanie’s deep understanding of the oncology industry and her ability to lead teams through complex projects make her a vital part of the organization’s success. Her dedication to providing high-quality solutions to our life science partners is a testament to her commitment to improving cancer patient care.

Jason Cash

Chief Financial Officer

Jason is an accomplished finance professional with over 20 years of experience in the pharmaceutical services industry. Throughout his career, he has demonstrated a keen ability to navigate high-growth organizations, delivering exceptional results. Before joining Aptitude Health, Jason served as the CFO of Veristat International, a global contract research organization. In this role, he led the financial strategy and played a pivotal role in driving the company’s growth and success. Jason’s wealth of experience and expertise in financial management make him an essential member of the leadership team. His strategic thinking and ability to drive results are highly respected within the industry.

Jez Moulding

Chief Executive Officer
Jez is a seasoned leader with over 20 years of experience in general management and regional president roles. He has a proven track record of success in the healthcare industry, having worked in the US, Japan, Australia, Korea, South Africa, France, and the UK for Sanofi, where he supported the launch of 10 new drugs across various therapeutic areas. As chief commercial officer at UDG Healthcare and EVP at Ashfield, Jez demonstrated his expertise in developing and implementing successful business strategies. He joined Aptitude Health from Pharmaspectra, an IQVIA business, where he served as CEO since 2018. Jez’s extensive experience in the pharmaceutical industry and his leadership skills make him an invaluable asset to the organization.
Aptitude Health
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.